Literature DB >> 16553927

Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004.

S Patrick Kachur1, Jeffrey Schulden, Catherine A Goodman, Herry Kassala, Berty Farida Elling, Rashid A Khatib, Louise M Causer, Saidi Mkikima, Salim Abdulla, Peter B Bloland.   

Abstract

OBJECTIVE: To determine the prevalence of malaria parasitemia and other common illnesses among drug store clients in one rural community, with a view to the potential role of specialist drug stores in expanding coverage of effective malaria treatment to households in highly endemic areas.
METHOD: Follow-back study of 2466 client visits selected from all 10 drug stores operating in the town of Ikwiriri between May 30 and August 31 2004. Of these, 521 (21.2%) were made by or on behalf of persons ill with fever or malaria. Two hundred and ninety three were eligible as residents of the surrounding nine villages and all agreed to participate in the study. Each patient was evaluated by a clinical officer and provided a blood sample for malaria on the day of the shop visit, either at the shop or at home.
RESULTS: Only 50 (17.1%) visits by or on behalf of febrile patients resulted in the purchase of an antimalarial drug, while an antipyretic medication was obtained at 226 visits (77.1%). Clinicians diagnosed malaria in 63.8% of patients. Malaria parasites were identified in blood film samples from 24.2% (95% CI: 19.6, 29.5). This is double the parasite prevalence rate of 10.7% (95% CI: 8.6, 13.1) obtained from a household survey of 1004 healthy individuals selected from these villages at the same time. It is not significantly lower than the prevalence observed among 880 clients presenting with fever at health facilities in the district: 29.7% (95% CI: 23.0, 37.3). The prevalence of malaria parasitemia among children younger than 5 years whose families sought fever treatment from drug stores (42.1%; 95% CI: 31.4, 53.5) was equal to that of children presenting with fever at health facilities (42.5%; 95% CI: 25.0, 62.2).
CONCLUSIONS: Currently, drug store clients do not obtain malaria-specific treatment in the majority of cases where it might be warranted. Parasitological findings indicate that drug store clients, especially children, are as likely to be infected with malaria as patients seeking care for similar illnesses at health facilities. Drug stores may be attractive partners for policy makers eager to engage the private retail sector in expanding coverage of malaria treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553927     DOI: 10.1111/j.1365-3156.2006.01588.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  25 in total

1.  Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial.

Authors:  Hugh Reyburn; Hilda Mbakilwa; Rose Mwangi; Ombeni Mwerinde; Raimos Olomi; Chris Drakeley; Christopher J M Whitty
Journal:  BMJ       Date:  2007-01-26

Review 2.  Reduction in the proportion of fevers associated with Plasmodium falciparum parasitaemia in Africa: a systematic review.

Authors:  Valérie D'Acremont; Christian Lengeler; Blaise Genton
Journal:  Malar J       Date:  2010-08-22       Impact factor: 2.979

3.  Determinants of use of intermittent preventive treatment of malaria in pregnancy: Jinja, Uganda.

Authors:  Laura R Sangaré; Andy Stergachis; Paula E Brentlinger; Barbra A Richardson; Sarah G Staedke; Mpungu S Kiwuwa; Noel S Weiss
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

Review 4.  Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved?

Authors:  Catherine Goodman; William Brieger; Alasdair Unwin; Anne Mills; Sylvia Meek; George Greer
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

5.  Drug shop regulation and malaria treatment in Tanzania--why do shops break the rules, and does it matter?

Authors:  Catherine Goodman; S Patrick Kachur; Salim Abdulla; Peter Bloland; Anne Mills
Journal:  Health Policy Plan       Date:  2007-10-04       Impact factor: 3.344

6.  Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study.

Authors:  Rashid A Khatib; Jacek Skarbinski; Joseph D Njau; Catherine A Goodman; Berty F Elling; Elizeus Kahigwa; Jacquelin M Roberts; John R MacArthur; Julie R Gutman; Abdunoor M Kabanywanyi; Ernest E Smith; Masha F Somi; Thomas Lyimo; Alex Mwita; Blaise Genton; Marcel Tanner; Anne Mills; Hassan Mshinda; Peter B Bloland; Salim M Abdulla; S Patrick Kachur
Journal:  Malar J       Date:  2012-04-30       Impact factor: 2.979

7.  Artemisinin-based combination therapy does not measurably reduce human infectiousness to vectors in a setting of intense malaria transmission.

Authors:  Bernadette J Huho; Gerard F Killeen; Heather M Ferguson; Adriana Tami; Christian Lengeler; J Derek Charlwood; Aniset Kihonda; Japhet Kihonda; S Patrick Kachur; Thomas A Smith; Salim Mk Abdulla
Journal:  Malar J       Date:  2012-04-18       Impact factor: 2.979

Review 8.  Examining characteristics, knowledge and regulatory practices of specialized drug shops in Sub-Saharan Africa: a systematic review of the literature.

Authors:  Francis N Wafula; Eric M Miriti; Catherine A Goodman
Journal:  BMC Health Serv Res       Date:  2012-07-27       Impact factor: 2.655

9.  Methods for implementing a medicine outlet survey: lessons from the anti-malarial market.

Authors:  Kathryn A O'Connell; Stephen Poyer; Tsione Solomon; Erik Munroe; Edith Patouillard; Julius Njogu; Illah Evance; Kara Hanson; Tanya Shewchuk; Catherine Goodman
Journal:  Malar J       Date:  2013-02-05       Impact factor: 2.979

10.  Treatment of fevers prior to introducing rapid diagnostic tests for malaria in registered drug shops in Uganda.

Authors:  Anthony K Mbonye; Sham Lal; Bonnie Cundill; Kristian Schultz Hansen; Siân Clarke; Pascal Magnussen
Journal:  Malar J       Date:  2013-04-16       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.